MedTrace Logo

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

NCT07357740 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-03-30

No results posted yet for this study

Summary

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

CagriSema

Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.

DRUG

Placebo CagriSema

Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-27
Primary Completion
2027-08-25
Completion
2027-10-13
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Greece
  • Malaysia
  • Serbia
  • Slovakia
  • Spain
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357740 on ClinicalTrials.gov